We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+12.59%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.15%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$216M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$129M |
| 3 |
Brown & Brown
BRO
|
+$121M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$116M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$90.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$144M |
| 2 |
MetLife
MET
|
+$97.2M |
| 3 |
Travelers Companies
TRV
|
+$91.9M |
| 4 |
Electronic Arts
EA
|
+$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.08% |
| 2 | Technology | 23.91% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
TKO Group
TKO
$13.8B
| $1.32M | 0.01% |
+7,242
| New | +$1.16M |
|
777
Healthpeak Properties
DOC
$14.9B
| $1.32M | 0.01% |
75,149
+16,046
| +27% | +$285K |
|
|
MNTN
778
MNTN Inc
MNTN
$704M
| $1.31M | 0.01% |
+60,000
| New | +$1.38M |
|
779
Domino's
DPZ
$12.1B
| $1.31M | 0.01% |
2,909
-82,795
| -97% | -$38.9M |
|
780
Fox Class A
FOXA
$24.6B
| $1.3M | 0.01% |
23,152
-631,565
| -96% | -$33.3M |
|
781
Prologis
PLD
$135B
| $1.28M | 0.01% |
+12,198
| New | +$1.28M |
|
782
Repligen
RGEN
$8.3B
| $1.28M | 0.01% |
10,268
-45,938
| -82% | -$5.85M |
|
783
Neurogene
NGNE
$656M
| $1.25M | 0.01% |
83,835
+425
| +0.5% | +$6.67K |
|
784
Insulet
PODD
$11.8B
| $1.24M | 0.01% |
+3,936
| New | +$1.14M |
|
785
C.H. Robinson
CHRW
$17.2B
| $1.23M | 0.01% |
12,843
+2,814
| +28% | +$264K |
|
786
News Corp Class A
NWSA
$15.1B
| $1.21M | 0.01% |
+40,802
| New | +$1.12M |
|
787
Alexandria Real Estate Equities
ARE
$9.24B
| $1.21M | 0.01% |
16,654
+3,639
| +28% | +$270K |
|
788
Mineralys Therapeutics
MLYS
$2.27B
| $1.19M | 0.01% |
87,868
+40,206
| +84% | +$583K |
|
789
Ralph Lauren
RL
$22.6B
| $1.18M | 0.01% |
4,309
+940
| +28% | +$233K |
|
790
Pinnacle West Capital
PNW
$12.2B
| $1.15M | 0.01% |
12,899
+3,293
| +34% | +$301K |
|
791
Nurix Therapeutics
NRIX
$2.41B
| $1.14M | 0.01% |
100,271
+67
| +0.1% | +$724 |
|
792
Solventum
SOLV
$15.3B
| $1.14M | 0.01% |
14,973
+3,296
| +28% | +$233K |
|
793
J.M. Smucker
SJM
$12.6B
| $1.13M | 0.01% |
11,511
+2,521
| +28% | +$277K |
|
|
TERN
794
DELISTED
Terns Pharmaceuticals
TERN
| $1.13M | 0.01% |
301,612
| – | – |
|
795
Parker-Hannifin
PH
$126B
| $1.11M | 0.01% |
1,588
-26,618
| -94% | -$16.8M |
|
|
BBOT
796
BridgeBio Oncology
BBOT
$661M
| $1.1M | 0.01% |
103,247
| – | – |
|
797
Stoke Therapeutics
STOK
$1.84B
| $1.08M | 0.01% |
95,120
| – | – |
|
|
JBIO
798
Jade Biosciences
JBIO
$1.17B
| $1.06M | 0.01% |
+106,270
| New | +$3.62M |
|
799
EQT Corp
EQT
$33.5B
| $1.06M | 0.01% |
18,165
-500,773
| -96% | -$27M |
|
800
Conagra Brands
CAG
$7.14B
| $1.06M | 0.01% |
51,635
+11,309
| +28% | +$265K |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Woodline Partners held 1,090 positions worth $18.9B, up 23% from $15.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners deployed $2.11B of net new capital in Q2 2025, opening 199 new positions and adding to 468 existing holdings. Its largest new stake was Brown & Brown: 1,079,076 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $76M trimmed.
- Woodline Partners's largest Q2 2025 buy was Brown & Brown: 1,079,076 shares worth $120M.
- Woodline Partners added most to Microsoft in Q2 2025, an estimated $216M increase.
- Woodline Partners's biggest Q2 2025 reduction was SpringWorks Therapeutics, cutting an estimated $76M.
- Woodline Partners fully exited Lam Research in Q2 2025, selling an estimated $144M.
- Woodline Partners's ten largest holdings make up 15% of its $18.9B portfolio in Q2 2025.
- Woodline Partners opened 199 new positions and closed 179 in Q2 2025.
- Woodline Partners's portfolio value rose 23% quarter-over-quarter to $18.9B.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.